tradingkey.logo

Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19

ReutersMar 2, 2026 2:29 PM

- Bioxytran Inc BIXT.PK:

  • BIOXYTRAN INC: REPORTS POSITIVE PHASE 1B/2A CLINICAL STUDY RESULTS FOR PROLECTIN-M, BROAD-RANGE ANTIVIRAL DRUG IN MILD TO MODERATE COVID-19

  • BIOXYTRAN INC - NO SERIOUS ADVERSE EVENTS REPORTED, NO TREATMENT-RELATED DISCONTINUATIONS OCCURRED- SEC FILING

  • BIOXYTRAN INC - PROLECTIN-M WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS - SEC FILING

Source text: []

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI